While the results from ongoing clinical trials that target HPK1 kinase activity in immune cells for cancer immunotherapy remain to be determined, our results demonstrated that targeting of HPK1 kinase activity is a double-edged sword for patients either harboring mutant Kras or at increased risk for pancreatic cancer. This evidence concerns the gene KRAS and familial pancreatic carcinoma.